Abstract: The present invention provides a compound represented by formula (I), wherein in formula (I), R1 represents CH3, F, (CH2)n—F, NH—(CH2)n—F, O—(CH2)n—F or S—(CH2)n—F, and n represents an integer of 1 to 3.

Abstract: Compounds according to formula I or II are provided. Such compounds are useful in treating cancers, such as leukemia, colon cancer, breast cancer, or prostate cancer by beneficially inhibiting CYP17A1. Pharmaceutical compositions and methods including the compounds are also provided.

Abstract: The invention relates to novel peptidase substrates of formula (I): wherein R0, R1, R2, R3, R4, R5 and n are as defined in claim 1, and a method for detecting the presence of a catalytically active peptidase, by means of one of these substrates.

Abstract: Provided are compounds of formula (I) and methods of controlling insects, acarines, nematodes or molluscs, which comprises applying to a pest, to a locus of a pest, or to a plant susceptible to attack by a pest an insecticidally, acaricidally, nematicidally or molluscicidally effective amount of a compound of formula (I).

Abstract: A method for producing a product that comprises glycerol ketal of ethyl levulinate or propylene glycol ketal of ethyl levulinate comprises reacting either glycerol or propylene glycol with ethyl levulinate in the presence of a homogenous or heterogeneous catalyst system in a reactor system. The ethyl levulinate and either glycerol or propylene glycol are heated to remove water, polyol, and excess ethyl levulinate. The excess ethyl levulinate and polyol is recycled back to the reactor. The product is distilled in a specific fashion and optionally treated by means of a stabilizing agent or acid species removal bed, to obtain a composition comprising glycerol ketal of ethyl levulinate or propylene glycol ketal of ethyl levulinate wherein the composition comprises less than or equal to about 2 wt % contaminants.

Abstract: A solid pharmaceutical composition suitable for oral administration, comprising: (a) a S1P receptor modulator; (b) a filler, and (c) a cyclodextrin.

Abstract: A process of preparing a compound of formula (I) wherein R represents a linear or branched C5 alkyl group, as well as the use of such compounds in a fragrant and/or flavoring composition.

Abstract: A process is described for converting HMF to FDCA, comprising dissolving a quantity of HMF in water to form an aqueous solution including HMF, combining the aqueous solution including HMF with an oxygen source in the presence of a homogeneous metal salt catalyst, but in the substantial absence of any solvent for the HMF and the homogeneous metal salt catalyst other than water, and under conditions which are effective for oxidizing HMF in the presence of the catalyst to form FDCA, and then recovering an FDCA precipitate.

Abstract: The present disclosure relates to an anti-acne formulation comprising at least one active ingredient selected from the group consisting of coumarin based compounds of Formula I and Formula II; or pharmaceutically acceptable salts, polymorphs and derivatives thereof, and at least one pharmaceutically acceptable excipient. The present disclosure also relates to its application for preventing/curing/treating various acne conditions.

Abstract: Provided herein are methods for preparing alkylfurans, such as 2,5-dialkylfurans and 2-alkylfurans. Furfural or 5-alkylfurfural can be reacted with aniline or diaminobenzene, or derivatives thereof, to form the corresponding imine, which can be reduced to form alkylfurans and to regenerate the aniline or diaminobenzene, or derivatives thereof. The alkylfuran may be, for example, 2,5-dimethylfuran or 2-methylfuran.

Abstract: The invention provides a method for preparing a carboxylic acid, which method includes the steps of providing magnesium carboxylate, wherein the carboxylic acid corresponding with the carboxylate has a solubility in water at 20° C. of 80 g/100 g water or less; acidifying the magnesium carboxylate with HCl, thereby obtaining a solution comprising carboxylic acid and magnesium chloride (MgCl2); optionally a concentration step, wherein the solution comprising carboxylic acid and MgCl2 is concentrated; precipitating the carboxylic acid from the solution comprising the carboxylic acid and MgCl2, thereby obtaining a carboxylic acid precipitate and a MgCl2 solution.

Abstract: Linear or cyclic carbonates as potential monomers for isocyanate-free polyurethanes and polycarbonates were prepared from polyols and dialkyl carbonates or diphenyl carbonates. This invention was developed to produce linear or cyclic carbonates with or without using catalysts. Polyol compounds were reacted with carbonates such as dimethyl carbonate and diethyl carbonate to produce the corresponding linear and/or cyclic carbonate.

Abstract: The present invention relates to a production method for an anhydro sugar alcohol having a markedly reduced ion content and improved color characteristics, and, more specifically, relates to a method for producing an anhydrous sugar alcohol having a markedly reduced ion content, markedly lowered electrical conductivity and improved color characteristics, which is obtained by subjecting hydrogenated sugar (sugar alcohol) to a dehydration reaction and thereby converting same to an anhydrous sugar alcohol and then subjecting distilled water, which has been isolated through a distillation step, to a decolorizing process using activated carbon, and subsequently bringing the resulting decolorized substance into contact with an ion exchange resin.

Abstract: The present invention provides N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines derivatives that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.

Abstract: The invention is generally directed to a process of producing purified gamma- and/or delta-tocotrienols from tocol-rich oils or distillates, such as rice bran oil deodorizer distillate or palm oil. The process produces a gamma- and/or delta-tocotrienol-rich fraction in a high proportion of ?-T3 and/or ?-T3 while minimizing the presence of alpha isomers from the tocol-rich oil or distillate. The ?-T3- and/or ?-T3-rich fraction comprises about 95% of total tocols, with the process yielding ?-T3 in approximately 10% and ?-T3 in about 3%, with each having purity in excess of approximately 95%. The process utilizes flash or other low pressure chromatography to provide rapid isolation of gamma- and/or delta-tocotrienol from the tocol-rich oil or distillate.

Abstract: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.

Abstract: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.

Abstract: The present invention, the present invention relates to an organic semiconductor material having a benzothienobenzothiophene skeleton, an organic semiconductor ink containing the organic semiconductor material, and an organic transistor using the organic semiconductor material. An object of the present invention is to provide an organic semiconductor material that easily provides a film having a high carrier mobility without the need for a complicated process. It was found that a BTBT derivative having a particular arylene acetylene structure is crystallized by way of a high-order liquid crystal phase having a highly ordered molecular arrangement, and thus the BTBT derivative easily forms a film having a high mobility without requiring complicated heat treatment even when the film is formed by printing. This finding led to the achievement of the object.

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract: The present invention relates to a chiral oxamide of formula (I) useful as an intermediate in the preparation of dorzolamide, and to the preparation thereof. The invention also relates to the preparation of dorzolamide, to the hydrochloride salt thereof, and to the active ingredient contained in a drug useful in the treatment of glaucoma, by means of the intermediate of formula (I).